medwireNews 10 August 2015
Oral contraceptive use protects against endometrial cancer, with effects persisting for decades after cessation of use, shows a meta-analysis of individual patient data published in The Lancet Oncology.
Read more here
medwireNews 10 August 2015
Oral contraceptive use protects against endometrial cancer, with effects persisting for decades after cessation of use, shows a meta-analysis of individual patient data published in The Lancet Oncology.
Read more here
Hi SASHA readers,
Some people have pointed out that the link in the previous post “Depo-Provera Linked to Increased HIV Risk in Africa” goes to a login page which locks them out. I found the article through google, and it turns out you can only access it in you go in that way, i.e. via google results. I was not aware of this when i posted it.
Cheers,
SASHA
Medscape, January 09, 2015
The injectable contraceptive depot medroxyprogesterone (Depo-Provera or DMPA) is associated with elevated risk for HIV infection among women in low-income or middle-income countries of sub-Saharan Africa, according to a study.
The mechanism behind a link between DMPA and HIV infection is not known.
Read more here